Combining Docetaxel and ATRA for Prostate Cancer Treatment
Author Information
Author(s): Kucukzeybek Yuksel, Gul Mustafa K, Cengiz Ercument, Erten Cigdem, Karaca Burcak, Gorumlu Gurbuz, Atmaca Harika, Uzunoglu Selim, Karabulut Bulent, Sanli Ulus A, Uslu Ruchan
Primary Institution: Ege University, Bornova, Izmir, Turkey
Hypothesis
The combination of docetaxel and all-trans retinoic acid (ATRA) enhances cytotoxicity and apoptosis in hormone- and drug-resistant prostate cancer cells.
Conclusion
The combination of docetaxel and ATRA is effective in reducing cancer cell growth and may allow for lower doses of docetaxel, minimizing side effects while maintaining therapeutic efficacy.
Supporting Evidence
- Docetaxel and ATRA were found to be synergistically cytotoxic in DU-145 cells.
- The combination treatment significantly downregulated survivin (BIRC5), MCL-1, and LTβR genes.
- Caspase 3/7 activity increased significantly with the combination treatment compared to either agent alone.
Takeaway
This study shows that using two cancer-fighting medicines together can work better than using just one, helping to kill more cancer cells.
Methodology
The study used XTT cell proliferation assays, DNA fragmentation assays, and caspase 3/7 activity measurements to evaluate the effects of docetaxel and ATRA on DU-145 prostate cancer cells.
Limitations
The study was conducted in vitro, and results may not fully translate to in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website